Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child

Pediatric Blood and Cancer

Volumn 53, Issue 3, 2009, Pages 468-471

  Maurer, Scott H ^a   Wilimas, Judith A ^a   Wang, Winfred C ^a   Reiss, Ulrike M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Children; Direct thrombin inhibitor; Fondaparinux; Heparin induced thrombocytopenia; Warfarin

Indexed keywords

ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CEFAZOLIN; CHLORAL HYDRATE; CORTICOSTEROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; HOMOCYSTEINE; LIPOPROTEIN A; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; RANITIDINE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ABDOMINAL PAIN; ACTIVATED PROTEIN C RESISTANCE; ARTICLE; BLEEDING; BODY WEIGHT; CASE REPORT; CATHETER; CHILD; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; INFERIOR CAVA VEIN OBSTRUCTION; INTERNATIONAL NORMALIZED RATIO; KLEBSIELLA PNEUMONIAE INFECTION; LEG THROMBOSIS; LOBAR PNEUMONIA; LUNG EMBOLISM; LUNG HEMORRHAGE; OXYGEN THERAPY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; SCHOOL CHILD; SEPSIS; SIDE EFFECT; STENT; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT DURATION;

ANTICOAGULANTS; CHILD; FEMALE; HEPARIN; HUMANS; POLYSACCHARIDES; THROMBOCYTOPENIA; THROMBOSIS; WARFARIN;

EID: 67651227629     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22067     Document Type: Article

References (20)

1. Dager WE, Dougherty JA, Nguyen PH, et al. Heparin-induced thrombocytopenia: Treatment options and special considerations. Pharmacotherapy 2007;27:564-587. (Pubitemid 46536238)
2. Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: An update. Semin Thromb Haemost 2008;34:86-96. (Pubitemid 351640884)
3. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update. Thromb Res 2006;118:165-176. (Pubitemid 43816669)
4. Klenner AF, Lubenow N, Raschke R, et al. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost 2004;91:719-724. (Pubitemid 38477452)
5. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Haematol 2003;121:535-555.
6. Young G, Tarantino MD, Wohrley J, et al. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007;5:1654-1659. (Pubitemid 47091407)
7. Hursting M, Dubb J. Argatroban anticoagulation in pediatric patients: A literature analysis. J Pediatr Hematol Oncol 2006;28:4-10. (Pubitemid 43361611)
8. Papadopoulos S, Flynn J, Lewis D. Fondaparinux as a treatment option in heparin-induced thrombocytopenia. Pharmacotherapy 2008;27:921-926.
9. Rayapudi S, Torres A, Jr., Deshpande G, et al. Bivalirudin for anticoagulation in children. Pediatr Blood Cancer 2008;51:798-801.
10. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:340-380. (Pubitemid 351892970)
11. Hursting M, Zehnder J, Becker J, et al. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice on thromboplastin used. Clin Chem 1999;45:409-411. (Pubitemid 29114179)
12. Sheth S, DiCicco M, Hursting M, et al. Interpreting the international normalized ratio (INT) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435-440. (Pubitemid 32233014)
13. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2005;11:279-287.
14. Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 2005;25:157-164. (Pubitemid 40223477)
15. Walenga JM, Fasanella A, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Haemost 1999;25:61-66. (Pubitemid 29230567)
16. Ciavarella N, Coccheri S, Gensini G, et al. Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants. Thromb Res 1980;19:493-502. (Pubitemid 11245307)
17. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:2653-2654.
18. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008;99:779-781.
19. Raffini L, Cahill AM, Hellinger J, et al. A prospective observational study of IVC filters in pediatric patients. Pediatr Blood Cancer 2008;51:517-520.
20. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Guidelines (8th Edition). Chest 2008;133:887s-968s. (Pubitemid 351892979)